Cara Therapeutics (CARA): Raising PT After Management Meetings - Piper Jaffray

November 15, 2016 6:52 AM EST
Get Alerts CARA Hot Sheet
Price: $11.43 -1.47%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade CARA Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Cara Therapeutics (NASDAQ: CARA) and raised his price target to $21 after hosting management for investor meetings.

The analyst sees the potential for significant upside driven by clinical efficacy data from the company’s three lead programs - IV ‘845 in acute pain, IV ‘845 in uremic pruritus, oral ‘845 in OA – within the next 3-6 months. The belief is based on both the time with management and the analyst's ongoing due diligence.

The analyst stated "Cara not only has a differentiated, broadly applicable pipeline in a product for pain and itch, but has thoughtfully designed current studies to maximize signal in what can be noisy indications. After what has been mostly an execution year in 2016, we expect these design choices to pay off with positive top-line results and interim updates in 1H17. In advance of potentially transformational clinical progress for Cara from three near-term shots on the KOR goal".

The new $21 PT jumps from $16 on rolling forward the discount period to YE17 from YE16 for all programs without changing the 25% discount rate.

For an analyst ratings summary and ratings history on Cara Therapeutics click here. For more ratings news on Cara Therapeutics click here.

Shares of Cara Therapeutics closed at $9.32 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, Management Comments

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment